Navigation Links
New Data on EMA401 in Model of Diabetic Neuropathy Presented at 21st Annual NEURODIAB Meeting
Date:9/12/2011

MELBOURNE, Australia, September 12, 2011 /PRNewswire/ --

 

EMA401 Shown to Improve Nerve and Neurovascular Function

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces the presentation of new data from a study of EMA401 in a model of diabetic neuropathy. EMA401 is an angiotensin II type 2 (AT2) receptor antagonist currently in clinical development for a number of neuropathic pain indications.

The new data were presented at the 21st annual meeting of the Diabetic Neuropathy Study Group of the European Association for the Study of Diabetes, NEURODIAB, on the 11th September by Professors Norman Cameron and Mary Cotter of the University of Aberdeen.

Diabetic neuropathy is a side effect of diabetes that is characterized by the peripheral nerves not functioning properly. Patients present with symptoms that include pain but can also include sensory loss and reduced reflex. Diminished nerve conduction velocities resulting from damage to the peripheral nervous system have also been linked to other serious side effects of diabetes such as ulcers of the feet and legs which can ultimately lead to amputation.

In the new study, initiated by Spinifex Pharmaceuticals, EMA401 was shown to correct motor and sensory nerve conduction velocity (NCV) in an established animal model of diabetes. EMA401 also reduced pain and heat sensitivity and corrected sciatic nerve nutritive blood flow. EMA401 was effective at a dose of 1 mg/kg/day and no CNS side effects were observed, consistent with earlier studies at this and higher doses.

Spinifex Pharmaceuticals CEO Tom McCarthy said: "The discovery that AT2 receptor antagonists offer an innovative approach to the treatment of neuropathic and inflammatory pain was originally made by Professor Maree Smith at The University of Queensland and we have good earlier data on the impact of EMA401 on neuropathic pain in pre-clinical models. This new study we initiated with Professors Cameron and Cotter not only reinforces our earlier data on the impact of EMA401 on neuropathic pain but also confirms our hypothesis that EMA401 may treat the underlying nerve conduction velocity deficits that are the hallmark of diabetic neuropathy. This expands the range of potential indications for the compound and, importantly, provides a new therapeutic target for what is a particularly devastating form of neuropathy."

Professor Norman Cameron said: "Inhibition of the renin-angiotensin system can reduce the development of diabetic complications including neuropathy but most attention has focussed on AT1 receptor-mediated mechanisms. This is the first study of the effect of an AT2 receptor antagonist on nerve function in an appropriate diabetes model. In showing EMA401 corrects aspects of neurovascular dysfunction the data suggests the AT2 receptor is a valuable new potential therapeutic target in diabetic neuropathy."

Spinifex acquired the initial technology underpinning EMA401 from The University of Queensland and has conducted a comprehensive pre-clinical and early clinical development program. EMA401 has shown efficacy in a number of relevant models, good human safety and pharmacokinetics in Phase 1 studies and the first of three Phase 2 clinical trials will be initiated shortly.

Spinifex's clinical program for EMA401 is initially focused on neuropathic pain, an area of high unmet medical need. The market for neuropathic pain treatments is expected to continue to increase and is projected to reach US$6.2 billion by 2017. Despite this growth, current therapy needs to be improved as a significant proportion of neuropathic pain patients don't respond to current therapy and these treatments have dose-limiting side effects. As a result, EMA401 is being developed as a potential first-in-class oral treatment for neuropathic pain and related symptoms without central nervous system side effects.

The program from the NEURODIAB 2011 meeting can be found by following the links from http://www.neurodiab-easd.org .

Spinifex Pharmaceuticals

Spinifex Pharmaceuticals is an Australian biotechnology company developing new drug candidates for the treatment and management of pain.

Established in 2005 and based in Melbourne, Spinifex has applied its world-class drug development capabilities to advance product candidates. Its lead product EMA401 is under development as a potential first-in-class oral treatment for neuropathic pain and related symptoms without CNS side effects. Spinifex is conducting Phase 2 clinical trials with EMA401 in a number of neuropathic pain conditions. Spinifex investors are GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest.

http://www.spinifexpharma.com.au

For more information please contact:

Company
Dr Tom McCarthy                    
CEO Spinifex Pharmaceuticals            
Tel:  +61(0)3-9938-1205                
Email: tom.mccarthy@spinifexpharma.com.au        

Media
Chris Gardner/Nina Enegren
Citigate Dewe Rogerson
Tel:  +44(0)20-7638-9571
Email: nina.enegren@citigatedr.co.uk



'/>"/>
SOURCE Spinifex Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bourns Introduces Two New Industrial-Grade Panel Control Models
2. St. Vincents Medical Center Extends Licensing Agreement With Streamline Health and Migrates to SaaS Model
3. Diplomat Specialty Pharmacy 2011 Patient Satisfaction Survey Results Affirm Success of Companys Patient Focused Model
4. ChemoCentryx Reports Novel CCR2 Antagonist Significantly Improves Kidney Function and Hyperglycemia in Models of Type 2 Diabetes
5. Health Economics Model Shows That Dermagraft® Combined With Conventional Care is a Cost-Effective Treatment for Diabetic Foot Ulcers in Medicare and Commercially Insured Populations
6. GT Life Sciences Broadens Intellectual Property Portfolio with Issuance of U.S. Patent on Core Computational Systems and Methods for Genomic-based Metabolic Modeling
7. Objet to Showcase Exceptionally Detailed and Accurate Dental Models at LMT LAB DAY West
8. Nonin Medical Launches Low Power Xpod®, Model 3012LP, OEM Pulse Oximeter Globally
9. Plato BioPharma, Inc. Sponsors Novel Disease Model Award
10. Pathfinder Cells Demonstrate Ability to Regenerate Damaged Tissue and Restore Pancreatic Function in a Diabetic Mouse Model
11. New Model Provides Insights Into Intravenous and Subcutaneous Immunoglobulin Pharmacokinetics in Patients With Primary Immunodeficiencies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... financial data derived from varied research sources to present unique ... on the market during the next five years, including a ... markets, regional and country level analysis. The report provides a ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ...
(Date:6/23/2016)... Calif. , June 23, 2016 ... CST on Thursday, July 7, 2016 , , , , ... ) , , , , EXPERT PANELISTS:  , , ... Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar ... The global pharmaceutical industry is witnessing an exceptional ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... , ... June 26, 2016 , ... On June 10-11, ... of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, ... the city’s history as home to some of the world’s leading providers of cereal ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
Breaking Medicine News(10 mins):